Diabetes and cancer relationships

Journal of Diabetes

Volumn 5, Issue 4, 2013, Pages 378-390

  Wang, Tiange ^a,b,c   Ning, Guang ^a,b,c   Bloomgarden, Zachary ^d  

^a BEIJING HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c E Institutes of Shanghai Universities   (China)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Diabetes; Diabetes treatment; Epidemiology; Randomized controlled trial

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; C PEPTIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLUCOSE; HUMAN INSULIN; INDAPAMIDE PLUS PERINDOPRIL; INSULIN; INSULIN GLARGINE; INSULIN RECEPTOR; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; SULFONYLUREA;

BARIATRIC SURGERY; BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COLON CANCER; COLORECTAL CANCER; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDUCED CANCER; DRUG SAFETY; ENDOMETRIUM CANCER; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FOLLOW UP; GALLBLADDER CANCER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN CLEARANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TREATMENT; INSULINEMIA; KIDNEY CARCINOMA; LEUKEMIA; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; META ANALYSIS (TOPIC); MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; OBESITY; OVERALL SURVIVAL; PANCREAS CANCER; POSTMENOPAUSE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; REVIEW; SECOND CANCER; STOMACH CANCER; SYSTEMATIC REVIEW (TOPIC); THYROID CANCER; UTERINE CERVIX CANCER;

CANCER; DIABETES; DIABETES TREATMENT; EPIDEMIOLOGY; RANDOMIZED CONTROLLED TRIAL;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN RESISTANCE; NEOPLASMS; OBESITY; OBSERVATIONAL STUDY AS TOPIC; PROGNOSIS;

EID: 84887018056     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12057     Document Type: Review

References (167)

1. Jee SH, Ohrr H, Sull JW etal. Fasting serum glucose level and cancer risk in Korean men and women. JAMA. 2005; 293: 194-202.
2. Rapp K, Schroeder J, Klenk J etal. Fasting blood glucose and cancer risk in a cohort of more than 140000 adults in Austria. Diabetologia. 2006; 49: 945-952.
3. Stattin P, Björ O, Ferrari P etal. Prospective study of hyperglycemia and cancer risk. Diabetes Care. 2007; 30: 561-567.
4. Tulinius H, Sigfusson N, Sigvaldason H, Bjarnadottir K, Tryggvadottir L. Risk factors for malignant diseases: A cohort study on a population of 22946 Icelanders. Cancer Epidemiol Biomarkers Prev. 1997; 6: 863-873.
5. Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Post-load plasma glucose and cancer mortality in middle-aged men and women. 12-year follow-up findings of the Chicago Heart Association Detection Project in Industry. Am J Epidemiol. 1990; 131: 254-262.
6. Saydah SH, Loria CM, Eberhardt MS, Brancati FL. Abnormal glucose tolerance and the risk of cancer death in the United States. Am J Epidemiol. 2003; 157: 1092-1100.
7. Stocks T, Rapp K, Bjørge T etal. Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): Analysis of six prospective cohorts. PLoS Med. 2009; 6: e1000201.
8. Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: A meta-analysis. Int J Cancer. 2007; 121: 856-862.
9. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst. 2005; 97: 1679-1687.
10. Larsson SC, Orsini N, Brismar K, Wolk A. Diabetes mellitus and risk of bladder cancer: A meta-analysis. Diabetologia. 2006; 49: 2819-2823.
11. Friberg E, Orsini N, Mantzoros CS, Wolk A. Diabetes mellitus and risk of endometrial cancer: A meta-analysis. Diabetologia. 2007; 50: 1365-1374.
12. El-Serag HB, Hampel H, Javadi F. The association between diabetes and hepatocellular carcinoma: A systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006; 4: 369-380.
13. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: A meta-analysis of 36 studies. Br J Cancer. 2005; 92: 2076-2083.
14. Barone BB, Yeh HC, Snyder CF etal. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA. 2008; 300: 2754-2764.
15. Bonovas S, Filioussi K, Tsantes A. Diabetes mellitus and risk of prostate cancer: A meta-analysis. Diabetologia. 2004; 47: 1071-1078.
16. Waters KM, Henderson BE, Stram DO, Wan P, Kolonel LN, Haiman CA. Association of diabetes with prostate cancer risk in the multiethnic cohort. Am J Epidemiol. 2009; 169: 937-945.
17. Dandona P, Dhindsa S, Chaudhuri A, Bhatia V, Topiwala S, Mohanty P. Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med. 2008; 8: 816-828.
18. Werny DM, Saraiya M, Gregg EW. Prostate-specific antigen values in diabetic and nondiabetic US men, 2001-2002. Am J Epidemiol. 2006; 164: 978-983.
19. Gapstur SM, Gann PH, Colangelo LA etal. Postload plasma glucose concentration and 27-year prostate cancer mortality (United States). Cancer Causes Control. 2001; 12: 763-772.
20. Hammarsten J, Högstedt B. Hyperinsulinaemia: A prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005; 41: 2887-2895.
21. D'Amico AV, Braccioforte MH, Moran BJ, Chen MH. Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010; 77: 1329-1337.
22. Snyder CF, Stein KB, Barone BB etal. Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis. 2010; 13: 58-64.
23. World Cancer Research Fund/American Institute for Cancer Research. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective, 2nd edn. American Institute for Cancer Research, Washington, DC, 2007.
24. Demark-Wahnefried W, Platz EA, Ligibel JA etal. The role of obesity in cancer survival and recurrence. Cancer Epidemiol Biomarkers Prev. 2012; 21: 1244-1259.
25. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371: 569-578.
26. Canoy D, Wareham N, Luben R etal. Cigarette smoking and fat distribution in 21828 British men and women: A population-based study. Obes Res. 2005; 13: 1466-1475.
27. Druesne-Pecollo N, Touvier M, Barrandon E etal. Excess body weight and second primary cancer risk after breast cancer: A systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat. 2012; 135: 647-654.
28. Adams TD, Stroup AM, Gress RE etal. Cancer incidence and mortality after gastric bypass surgery. Obesity. 2009; 17: 796-802.
29. Ostlund MP, Lu Y, Lagergren J. Risk of obesity-related cancer after obesity surgery in a population-based cohort study. Ann Surg. 2010; 252: 972-976.
30. Christou NV, Lieberman M, Sampalis F, Sampalis JS. Bariatric surgery reduces cancer risk in morbidly obese patients. Surg Obes Relat Dis. 2008; 4: 691-695.
31. Sjöström L, Gummesson A, Sjöström CD etal. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): A prospective, controlled intervention trial. Lancet Oncol. 2009; 10: 653-662.
32. Birks S, Peeters A, Backholer K, O'Brien P, Brown W. A systematic review of the impact of weight loss on cancer incidence and mortality. Obes Rev. 2012; 13: 868-891.
33. Becker S, Dossus L, Kaaks R. Obesity related hyperinsulinaemia and hyperglycaemia and cancer development. Arch Physiol Biochem. 2009; 115: 86-96.
34. Bonser AM, Garcia-Webb P. C-Peptide measurement: Methods and clinical utility. Crit Rev Clin Lab Sci. 1984; 19: 297-352.
35. Erdmann J, Pöhnl K, Mayr M etal. Disturbances of basal and postprandial insulin secretion and clearance in obese patients with type 2 diabetes mellitus. Horm Metab Res. 2012; 44: 60-69.
36. Stefanovski D, Richey JM, Woolcott O etal. Consistency of the disposition index in the face of diet induced insulin resistance: Potential role of FFA. PLoS ONE. 2011; 6: e18134.
37. Erdmann J, Mayr M, Oppel U, Sypchenko O, Wagenpfeil S, Schusdziarra V. Weight-dependent differential contribution of insulin secretion and clearance to hyperinsulinemia of obesity. Regul Pept. 2009; 152: 1-7.
38. Lee CC, Haffner SM, Wagenknecht LE etal. Insulin clearance and the incidence of type 2 diabetes in Hispanics and African Americans: The IRAS Family study. Diabetes Care. 2013; 36: 901-907.
39. Gunter MJ, Hoover DR, Yu H etal. Insulin, insulin-like growth factor-1, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. Cancer Res. 2008; 68: 329-337.
40. Michaud DS, Wolpin B, Giovannucci E etal. Prediagnostic plasma C-peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev. 2007; 16: 2101-2109.
41. Verheus M, Peeters PH, Rinaldi S etal. Serum C-peptide levels and breast cancer risk: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2006; 119: 659-667.
42. Gunter MJ, Hoover DR, Yu H etal. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009; 101: 48-60.
43. Cust AE, Allen NE, Rinaldi S etal. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk: Results from the European prospective investigation into cancer and nutrition. Int J Cancer. 2007; 120: 2656-2664.
44. Gunter MJ, Hoover DR, Yu H etal. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17: 921-929.
45. Muti P, Quattrin T, Grant BJ etal. Fasting glucose is a risk factor for breast cancer: A prospective study. Cancer Epidemiol Biomarkers Prev. 2002; 11: 1361-1368.
46. Roddam AW, Allen NE, Appleby P etal. Insulin-like growth factors, their binding proteins, and prostate cancer risk: Analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008; 149: 461-471.
47. Ben Sahra I, Laurent K, Loubat A etal. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27: 3576-3586.
48. Williams T, Brenman JE. LKB1 and AMPK in cell polarity and division. Trends Cell Biol. 2008; 18: 193-198.
49. Zhang ZJ, Zheng ZJ, Kan H etal. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: A meta-analysis. Diabetes Care. 2011; 34: 2323-2328.
50. Chlebowski RT, McTiernan A, Wactawski-Wende J etal. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol. 2012; 30: 2844-2852.
51. Col NF, Ochs L, Springmann V, Aragaki AK, Chlebowski RT. Metformin and breast cancer risk: A meta-analysis and critical literature review. Breast Cancer Res Treat. 2012; 135: 639-646.
52. Mazzone PJ, Rai H, Beukemann M, Xu M, Jain AK, Sasidhar M. The effect of metformin and thiazolidinedione use on lung cancer in diabetics. BMC Cancer. 2012; 12: 410.
53. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of antidiabetic agents and the risk of pancreatic cancer: A case-control analysis. Am J Gastroenterol. 2012; 107: 620-626.
54. Bodmer M, Becker C, Meier C, Jick SS, Meier CR. Use of metformin and the risk of ovarian cancer: A case-control analysis. Gynecol Oncol. 2011; 123: 200-204.
55. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Anti-diabetic medications and the risk of hepatocellular cancer: A systematic review and meta-analysis. Am J Gastroenterol. 2013; 108: 881-91; quiz 892.
56. Skinner HD, McCurdy MR, Echeverria AE etal. Metformin use and improved response to therapy in esophageal adenocarcinoma. Acta Oncol. 2013; 52: 1002-1009.
57. He XX, Tu SM, Lee MH, Yeung SC. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011; 22: 2640-2645.
58. + breast cancer. Ann Oncol. 2012; 23: 1771-1780.
59. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care. 2010; 33: 322-326.
60. Kubota T, Koshizuka K, Williamson EA etal. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998; 58: 3344-3352.
61. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2001; 86: 2170-2177.
62. Bosetti C, Rosato V, Buniato D, Zambon A, La Vecchia C, Corrao G. Cancer risk for patients using thiazolidinediones for type 2 diabetes: A meta-analysis. Oncologist. 2013; 18: 148-156.
63. Marin HE, Peraza MA, Billin AN etal. Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis. Cancer Res. 2006; 66: 4394-4401.
64. Wang D, Ning W, Xie D, Guo L, DuBois RN. Peroxisome proliferator-activated receptor γ confers resistance to peroxisome proliferator-activated receptor γ-induced apoptosis in colorectal cancer cells. Oncogene. 2012; 31: 1013-1023.
65. Galli A, Ceni E, Mello T etal. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus-transgenic mice by peroxisome proliferator-activated receptor gamma-independent regulation of nucleophosmin. Hepatology. 2010; 52: 493-505.
66. Shen B, Chu ES, Zhao G etal. PPAR gamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer. 2012; 106: 1486-1494.
67. Chen SW, Tsan YT, Chen JD etal. Use of thiazolidinediones and the risk of colorectal cancer in patients with diabetes: A nationwide, population-based, case-control study. Diabetes Care. 2013; 36: 369-375.
68. Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: A meta-analysis. CMAJ. 2012; 184: E675-683.
69. Stephenson J. Diabetes drug may be associated with increase in risk of bladder cancer. JAMA. 2011; 306: 143.
70. Lewis JD, Ferrara A, Peng T etal. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care. 2011; 34: 916-922.
71. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: A population-based cohort study. Diabetologia. 2012; 55: 1953-1962.
72. Tseng CH. Pioglitazone and bladder cancer: A population-based study of Taiwanese. Diabetes Care. 2012; 35: 278-280.
73. Lewis JD, Strom BL, Bilker W etal. Pioglitazone HCl (ACTOS) clinical study No. 01-03-TL-OPI-524 cohort study of pioglitazone and bladder cancer in patients with diabetes fourth interim analysis (8-year) report with data from January 1, 1997 to December 31, 2010. Available from: http://www.encepp.eu/encepp/openAttachment.htm?field=documents.otherDocument%5b0%5d&id=2903 (accessed 29 January 2013).
74. Ferwana M, Firwana B, Hasan R etal. Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies. Diabet Med. 2013; 30: 1026-1032.
75. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancer related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29: 254-258.
76. Jonasson JM, Ljung R, Talbäck M, Haglund B, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of malignancies: A population-based follow-up study in Sweden. Diabetologia. 2009; 52: 1745-1754.
77. Mannucci E, Monami M, Balzi D etal. Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients. Diabetes Care. 2010; 33: 1997-2003.
78. Hemkens LG, Grouven U, Bender R etal. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study. Diabetologia. 2009; 52: 1732-1744.
79. Li C, Zhao G, Okoro CA, Wen XJ, Ford ES, Balluz LS. Prevalence of diagnosed cancer according to duration of diagnosed diabetes and current insulin use among U.S. adults with diagnosed diabetes: Findings from the 2009 behavioral risk factor surveillance system. Diabetes Care. 2013; 36: 1569-1576.
80. Rosenstock J, Fonseca V, McGill JB etal. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: Findings from a 5 year randomised, open label study. Diabetologia. 2009; 52: 1971-1973.
81. Yang X, Ko GT, So WY etal. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: The HongKong diabetes registry. Diabetes. 2012; 59: 1254-1260.
82. Gu Y, Wang C, Zheng Y etal. Cancer incidence and mortality in patients with type 2 diabetes treated with human insulin: A cohort study in Shanghai. PLoS ONE. 2013; 8: e53411.
83. Andersson C, Vaag A, Selmer C etal. Risk of cancer in patients using glucose-lowering agents: A nationwide cohort study of 3.6 million people. BMJ Open. 2012; 2: e000433.
84. Chang CH, Lin JW, Wu LC, Lai MS, Chuang LM. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2012; 97: E1170-1175.
85. Baur DM, Klotsche J, Hamnvik OP etal. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. Metabolism. 2011; 60: 1363-1371.
86. Pierre-Eugene C, Pagesy P, Nguyen TT etal. Effect of insulin analogues on insulin/IGF1 hybrid receptors: Increased activation by glargine but not by its metabolites M1 and M2. PLoS ONE. 2012; 7: e41992.
87. Bolli GB, Hahn AD, Schmidt R etal. Plasma exposure to insulin glargine and its metabolites M1 and M2 after subcutaneous injection of therapeutic and supratherapeutic doses of glargine in subjects with type 1 diabetes. Diabetes Care. 2012; 35: 2626-2630.
88. Colhoun HM, SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: A study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009; 52: 1755-1765.
89. Ruiter R, Visser LE, van Herk-Sukel MP etal. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: Results from a large population-based follow-up study. Diabetologia. 2012; 55: 51-62.
90. Ljung R, Talbäck M, Haglund B, Jonasson JM, Gudbjörnsdòttir S, Steineck G. Insulin glargine use and short-term incidence of breast cancer: A four-year population-based observation. Acta Oncol. 2012; 51: 400-402.
91. Blin P, Lassalle R, Dureau-Pournin C etal. Insulin glargine and risk of cancer: A cohort study in the French National Healthcare Insurance Database. Diabetologia. 2012; 55: 644-653.
92. Pocock SJ, Smeeth L. Insulin glargine and malignancy: An unwarranted alarm. Lancet. 2009; 374: 511-513.
93. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52: 1766-1777.
94. Bloomgarden Z, Handelsman Y. Cancer mortality and insulin glargine. J Diabetes. 2009; 1: 131-133.
95. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 2012; 12: 159-169.
96. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: A systematic review and meta-analysis. Am J Gastroenterol. 2013; 108: 510-519; quiz 520.
97. Thakkar B, Aronis KN, Vamvini MT, Shields K, Mantzoros CS. Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: A Meta-analysis using primary data of published studies. Metabolism. 2013; 62: 922-934.
98. Soranna D, Scotti L, Zambon A etal. Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: A meta-analysis. Oncologist. 2012; 17: 813-822.
99. Yang X, So WY, Ma RC etal. Use of sulphonylurea and cancer in type 2 diabetes: The Hong Kong Diabetes Registry. Diabetes Res Clin Pract. 2010; 90: 343-351.
100. Monami M, Lamanna C, Balzi D, Marchionni N, Mannucci E. Sulphonylureas and cancer: A case-control study. Acta Diabetol. 2009; 46: 279-284.
101. Sliwinska A, Blasiak J, Drzewoski J. Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells. Chem Biol Interact. 2006; 162: 259-267.
102. Stevens RJ, Ali R, Bankhead CR. Cancer outcomes and all-cause mortality in adults allocated to metformin: Systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia. 2012; 55: 2593-2603.
103. Home PD, Kahn SE, Jones NP etal. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia. 2010; 53: 1838-1845.
104. Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: A meta-analysis of randomized clinical trials. Diabetes Care. 2008; 31: 1455-1460.
105. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009; 52: 2499-2506.
106. ORIGIN Trial Investigators, Gerstein HC, Bosch J etal. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012; 367: 319-328.
107. Johnson JA, Bowker SL. Intensive glycaemic control and cancer risk in type 2 diabetes: A meta-analysis of major trials. Diabetologia. 2011; 54: 25-31.
108. ADVANCE Collaborative Group, Patel A, MacMahon S etal. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572.
109. Dormandy JA, Charbonnel B, Eckland DJ etal. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): A randomised controlled trial. Lancet. 2005; 366: 1279-1289.
110. Home PD, Pocock SJ, Beck-Nielsen H etal. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial. Lancet. 2009; 373: 2125-2135.
111. Norman G, Monteiro S, Salama S. Sample size calculations: Should the emperor's clothes be off the peg or made to measure? BMJ. 2012; 345: e5278.
112. Ullrich A, Gray A, Tam AW etal. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986; 5: 2503-2512.
113. Adams TE, Epa VC, Garrett TP, Ward CW. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci. 2000; 57: 1050-1093.
114. Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res. 2008; 14: 6364-6370.
115. Brogiolo W, Stocker H, Ikeya T etal. An evolutionarily conserved function of the Drosophila insulin receptor and insulin-like peptides in growth control. Curr Biol. 2001; 11: 213-221.
116. Drakas R, Tu X, Baserga R. Control of cell size through phosphorylation of upstream binding factor 1 by nuclear phosphatidylinositol 3-kinase. Proc Natl Acad Sci USA. 2004; 101: 9272-9276.
117. Burgering BM, Kops GJ. Cell cycle and death control: Long live Forkheads. Trends Biochem Sci. 2002; 27: 352-360.
118. Ohlsson C, Kley N, Werner H, LeRoith D. p53 regulates insulin-like growth factor-I (IGF-I) receptor expression and IGF-I-induced tyrosine phosphorylation in an osteosarcoma cell line: Interaction between p53 and Sp1. Endocrinology. 1998; 139: 1101-1107.
119. Surmacz E. Function of the IGF-I receptor in breast cancer. J Mammary Gland Biol Neoplasia. 2000; 5: 95-105.
120. Sgarra R, Rustighi A, Tessari MA etal. Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. FEBS Lett. 2004; 574: 1-8.
121. Pierantoni GM, Rinaldo C, Esposito F, Mottolese M, Soddu S, Fusco A. High mobility group A1 (HMGA1) proteins interact with p53 and inhibit its apoptotic activity. Cell Death Differ. 2006; 13: 1554-1563.
122. Frasca F, Pandini G, Scalia P etal. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol. 1999; 19: 3278-3288.
123. Vella V, Sciacca L, Pandini G etal. The IGF system in thyroid cancer: New concepts. Mol Pathol. 2001; 54: 121-124.
124. Vella V, Pandini G, Sciacca L etal. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab. 2002; 87: 245-254.
125. Mathieu MC, Clark GM, Allred DC, Goldfine ID, Vigneri R. Insulin receptor expression and clinical outcome in node-negative breast cancer. Proc Assoc Am Physicians. 1997; 109: 565-571.
126. Mosthaf L, Grako K, Dull TJ, Coussens L, Ullrich A, McClain DA. Functionally distinct insulin receptors generated by tissue-specific alternative splicing. EMBO J. 1990; 9: 2409-2413.
127. Seino S, Bell GI. Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commun. 1989; 159: 312-316.
128. - (IR-A) in cancer and other diseases: A review. Horm Metab Res. 2003; 35: 778-785.
129. Moller DE, Yokota A, Caro JF, Flier JS. Tissue-specific expression of two alternatively spliced insulin receptor mRNAs in man. Mol Endocrinol. 1989; 3: 1263-1269.
130. Denley A, Bonython ER, Booker GW etal. Structural determinants for highaffinity binding of insulin-like growth factor II to insulin receptor (IR)-A, the exon 11 minus isoform of the IR. Mol Endocrinol. 2004; 18: 2502-2512.
131. McClain DA. Different ligand affinities of the two human insulin receptor splice variants are reflected in parallel changes in sensitivity for insulin action. Mol Endocrinol. 1991; 5: 734-739.
132. Yamaguchi Y, Flier JS, Benecke H, Ransil BJ, Moller DE. Ligand-binding properties of the two isoforms of the human insulin receptor. Endocrinology. 1993; 132: 1132-1138.
133. Sciacca L, Prisco M, Wu A, Belfiore A, Vigneri R, Baserga R. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the presence or absence of IR substrate-1. Endocrinology. 2003; 144: 2650-2658.
134. Benecke H, Flier JS, Moller DE. Alternatively spliced variants of the insulin receptor protein. Expression in normal and diabetic human tissues. J Clin Invest. 1992; 89: 2066-2070.
135. Norgren S, Zierath J, Galuska D, Wallberg-Henriksson H, Luthman H. Differences in the ratio of RNA encoding two isoforms of the insulin receptor between control and NIDDM patients. The RNA variant without Exon 11 predominates in both groups. Diabetes. 1993; 42: 675-681.
136. Sbraccia P, D'Adamo M, Leonetti F etal. Chronic primary hyperinsulinaemia is associated with altered insulin receptor mRNA splicing in muscle of patients with insulinoma. Diabetologia. 1996; 39: 220-225.
137. Alvino CL, Ong SC, McNeil KA etal. Understanding the mechanism of insulin and insulin-like growth factor (IGF) receptor activation by IGF-II. PLoS ONE. 2011; 6: e27488.
138. Frasca F, Pandini G, Sciacca L etal. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem. 2008; 114: 23-37.
139. Papa V, Pezzino V, Costantino A etal. Elevated insulin receptor content in human breast cancer. J Clin Invest. 1990; 86: 1503-1510.
140. Sciacca L, Costantino A, Pandini G etal. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism. Oncogene. 1999; 18: 2471-2479.
141. Sciacca L, Mineo R, Pandini G, Murabito A, Vigneri R, Belfiore A. In IGF-I receptor-deficient leiomyosarcoma cells autocrine IGF-II induces cell invasion and protection from apoptosis via the insulin receptor isoform A. Oncogene. 2002; 21: 8240-8250.
142. Kalli KR, Falowo OI, Bale LK, Zschunke MA, Roche PC, Conover CA. Functional insulin receptors on human epithelial ovarian carcinoma cells: Implications for IGF-II mitogenic signaling. Endocrinology. 2002; 143: 3259-3267.
143. Whittaker J, Soos MA, Siddle K. Hybrid insulin receptors. Molecular mechanisms of negative-dominant mutations in receptor-mediated insulin resistance. Diabetes Care. 1990; 13: 576-581.
144. Soos MA, Field CE, Siddle K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem J. 1993; 290: 419-426.
145. Pandini G, Vigneri R, Costantino A etal. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: Evidence for a second mechanism of IGF-I signaling. Clin Cancer Res. 1999; 5: 1935-1944.
146. Belfiore A, Pandini G, Vella V, Squatrito S, Vigneri R. Insulin/IGF-I hybrid receptors play a major role in IGF-I signaling in thyroid cancer. Biochimie. 1999; 81: 403-407.
147. Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem. 2002; 277: 39684-39695.
148. Lukanova A, Lundin E, Zeleniuch-Jacquotte A etal. Body mass index, circulating levels of sex-steroid hormones, IGF-I and IGF-binding protein-3: A cross-sectional study in healthy women. Eur J Endocrinol. 2004; 150: 161-171.
149. Jenab M, Riboli E, Cleveland RJ etal. Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2007; 121: 368-376.
150. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011; 11: 886-895.
151. Bredel M, Scholtens DM, Yadav AK etal. NFKBIA deletion in glioblastomas. N Engl J Med. 2011; 364: 627-637.
152. Park EJ, Lee JH, Yu GY etal. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010; 140: 197-208.
153. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology. 2001; 121: 79-90.
154. Endo H, Hosono K, Uchiyama T etal. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. Gut. 2011; 60: 1363-1371.
155. Choi JH, Park SH, Leung PC, Choi KC. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab. 2005; 90: 207-210.
156. Catalano S, Mauro L, Marsico S etal. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem. 2004; 279: 19908-19915.
157. Fogarty S, Hardie DG. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta. 2010; 1804: 581-591.
158. Lam JB, Chow KH, Xu A etal. Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities. PLoS ONE. 2009; 4: e4968.
159. Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004; 5: 153-165.
160. Molloy CA, May FE, Westley BR. Insulin receptor substrate-1 expression is regulated by estrogen in the MCF-7 human breast cancer cell line. J Biol Chem. 2000; 275: 12565-12571.
161. Tang H, Liao Y, Chen G etal. Estrogen upregulates the IGF-1 signaling pathway in lung cancer through estrogen receptor-β. Med Oncol. 2012; 29: 2640-2648.
162. Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005; 11 (Suppl) 865s-870.
163. Richardson AE, Hamilton N, Davis W, Brito C, De León D. Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and -β via the IGF-1 and the insulin receptors in breast cancer cells. Growth Factors. 2011; 29: 82-93.
164. Mawson A, Lai A, Carroll JS, Sergio CM, Mitchell CJ, Sarcevic B. Estrogen and insulin/IGF-1 cooperatively stimulate cell cycle progression in MCF-7 breast cancer cells through differential regulation of c-Myc and cyclin D1. Mol Cell Endocrinol. 2005; 229: 161-173.
165. Klotz DM, Hewitt SC, Ciana P etal. Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem. 2002; 277: 8531-8537.
166. Calle EE, Kaaks R. Overweight, obesity and cancer: Epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004; 4: 579-591.
167. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: The role of the insulin-IGF axis. Trends Endocrinol Metab. 2006; 17: 328-336.